CA3067107A1 - Marqueurs de nephropathies - Google Patents

Marqueurs de nephropathies Download PDF

Info

Publication number
CA3067107A1
CA3067107A1 CA3067107A CA3067107A CA3067107A1 CA 3067107 A1 CA3067107 A1 CA 3067107A1 CA 3067107 A CA3067107 A CA 3067107A CA 3067107 A CA3067107 A CA 3067107A CA 3067107 A1 CA3067107 A1 CA 3067107A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
antibodies
fragments
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3067107A
Other languages
English (en)
Other versions
CA3067107C (fr
Inventor
Mahalakshmi Yerramilli
Michael Randolph Atkinson
Murthy V. S. N. Yerramilli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idexx Laboratories Inc
Original Assignee
Idexx Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idexx Laboratories Inc filed Critical Idexx Laboratories Inc
Priority to CA3155662A priority Critical patent/CA3155662C/fr
Publication of CA3067107A1 publication Critical patent/CA3067107A1/fr
Application granted granted Critical
Publication of CA3067107C publication Critical patent/CA3067107C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La présente invention concerne des réactifs et des procédés pour effectuer le diagnostic dune néphropathie. Plus précisément, des niveaux différentiels du métabolite inosine et des protéines : apolipoprotéine C-I, apolipoprotéine C-II, chaîne alpha du fibrinogène ou chaîne A-alpha du fibrinogène, kininogène, inhibiteur inter-alpha H4, cytokératine-10 de type I, cystatine A, cystatine B, et d'autres polypeptides et des fragments de ceux-ci fournissent des biomarqueurs de néphropathies.
CA3067107A 2010-06-03 2011-06-03 Marqueurs de nephropathies Active CA3067107C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3155662A CA3155662C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35118310P 2010-06-03 2010-06-03
US61/351,183 2010-06-03
US41128010P 2010-11-08 2010-11-08
US61/411,280 2010-11-08
CA2799536A CA2799536C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2799536A Division CA2799536C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3155662A Division CA3155662C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies

Publications (2)

Publication Number Publication Date
CA3067107A1 true CA3067107A1 (fr) 2011-12-08
CA3067107C CA3067107C (fr) 2022-07-12

Family

ID=44262847

Family Applications (3)

Application Number Title Priority Date Filing Date
CA3155662A Active CA3155662C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies
CA3067107A Active CA3067107C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies
CA2799536A Active CA2799536C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3155662A Active CA3155662C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2799536A Active CA2799536C (fr) 2010-06-03 2011-06-03 Marqueurs de nephropathies

Country Status (6)

Country Link
US (3) US10436797B2 (fr)
EP (3) EP3845904A1 (fr)
JP (4) JP5855094B2 (fr)
AU (1) AU2011261308C1 (fr)
CA (3) CA3155662C (fr)
WO (1) WO2011153469A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
CN103439442B (zh) * 2013-08-21 2014-09-17 上海交通大学医学院附属仁济医院 血浆中肌苷含量的测定方法
US10725052B2 (en) * 2016-03-02 2020-07-28 Idexx Laboratories, Inc. Methods and compositions for the detection and diagnosis of renal disease and periodontal disease
US11180539B2 (en) * 2016-03-29 2021-11-23 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
JP2018096710A (ja) * 2016-12-08 2018-06-21 国立大学法人金沢大学 血中タンパク質を測定することにより、ネフローゼ症候群の疾患活動性を判定する方法
ES2927438T3 (es) 2017-05-31 2022-11-04 Mars Inc Procedimientos de diagnóstico y tratamiento de la enfermedad renal crónica
US20210293829A1 (en) 2018-01-19 2021-09-23 Mars, Incorporated Biomarkers and classification algorithms for chronic kidney disease in cats
WO2020018463A1 (fr) 2018-07-14 2020-01-23 Mars, Incorporated Biomarqueurs et modèles de test pour la néphropathie chronique
JP2023528231A (ja) 2020-06-01 2023-07-04 マース インコーポレーテッド イヌの慢性腎臓病のためのシステム及び方法
CN112379093B (zh) * 2020-10-22 2023-06-16 上海良润生物医药科技有限公司 CST-Cathepsin复合物作为肿瘤诊断标志物的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
ATE433571T1 (de) 2001-10-02 2009-06-15 Ikagaku Co Ltd Methode zur diagnose von nierenerkrankungen
JP3398372B1 (ja) * 2001-10-02 2003-04-21 株式会社いかがく 腎疾患の診断用キット
NL1020962C2 (nl) * 2002-06-28 2003-12-30 Tno Therapie en prognose/monitoring bij sepsis en septische shock.
WO2005049806A2 (fr) * 2003-03-14 2005-06-02 Nuvelo, Inc. Nouveaux acides nucleiques et polypeptides
AU2004262369A1 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
US20070087448A1 (en) * 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
EP1842065B1 (fr) 2005-01-28 2010-12-01 Children's Medical Center Corporation Methodes de diagnostic et de pronostic du cancer de la vessie
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
JP2009502112A (ja) * 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 腎細胞癌を診断および処置するための方法
US7599893B2 (en) 2005-10-13 2009-10-06 Aureon Laboratories, Inc. Methods and systems for feature selection in machine learning based on feature contribution and model fitness
WO2007070021A1 (fr) 2005-12-09 2007-06-21 Nanobac Pharmaceuticals Incorporated Detection de la calcification de nanoparticules, et proteines y associees
EP2520935A3 (fr) 2006-08-09 2013-02-13 Homestead Clinical Corporation Protéines spécifiques d'organes et leurs procédés d'utilisation
CN101120904B (zh) * 2006-11-13 2011-06-29 李复生 癌症疾病治疗器
CN101679525B (zh) 2007-03-26 2013-06-19 诺瓦提斯公司 用于监测肾功能的预测性的肾安全性生物标志物和生物标志物标签
EP2535718B1 (fr) * 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Procédé de diagnostic précoce de maladie rénale
EP2185926B1 (fr) * 2007-08-03 2015-10-07 Virginia Commonwealth University Procédé pour diagnostiquer l'ischémie cardiaque aiguë
GB0807065D0 (en) * 2008-04-18 2008-05-21 Univ Leeds Novel scaffolds
EP2180322A1 (fr) * 2008-10-22 2010-04-28 BRAHMS Aktiengesellschaft Biomarqueurs de pronostic pour la progression d'une maladie de reins chroniques primaires
WO2010126146A1 (fr) 2009-04-30 2010-11-04 Tanaka Noriaki Procédé ou appareil pour déterminer la gravité des maladies rénales et procédé pour faire fonctionner ledit appareil
AU2010336392B2 (en) * 2009-12-23 2014-01-23 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
WO2011109830A2 (fr) * 2010-03-05 2011-09-09 Case Western Reserve University Biomarqueurs de protéines et cibles thérapeutiques pour des troubles rénaux

Also Published As

Publication number Publication date
JP5855094B2 (ja) 2016-02-09
EP3054301A1 (fr) 2016-08-10
US20200049719A1 (en) 2020-02-13
US11933792B2 (en) 2024-03-19
AU2011261308A1 (en) 2012-12-06
JP6861771B2 (ja) 2021-04-21
CA3067107C (fr) 2022-07-12
CA3155662C (fr) 2023-05-16
CA2799536A1 (fr) 2011-12-08
WO2011153469A1 (fr) 2011-12-08
JP2020073870A (ja) 2020-05-14
EP3054301A8 (fr) 2016-10-05
JP6580102B2 (ja) 2019-09-25
JP2016095312A (ja) 2016-05-26
US10436797B2 (en) 2019-10-08
AU2011261308C1 (en) 2016-02-18
CA2799536C (fr) 2020-03-10
AU2011261308B2 (en) 2015-09-17
US20230139188A1 (en) 2023-05-04
JP2018066733A (ja) 2018-04-26
JP2013527478A (ja) 2013-06-27
US20130130285A1 (en) 2013-05-23
EP2577315B1 (fr) 2017-04-12
US11435365B2 (en) 2022-09-06
JP6224680B2 (ja) 2017-11-01
EP3845904A1 (fr) 2021-07-07
EP2577315A1 (fr) 2013-04-10
CA3155662A1 (fr) 2011-12-08

Similar Documents

Publication Publication Date Title
US11933792B2 (en) Markers for renal disease
JP7022969B2 (ja) ＳＡＲＳ－ＣｏＶ－２感染症を診断するための方法および試薬
US20200239558A1 (en) Compositions, Devices, Kits and Methods for Detecting Hookworm
JP5580967B2 (ja) ブタ繁殖性呼吸器症候群ウイルスに対する抗体を検出するためのペプチド
US11204351B2 (en) Compositions and methods for identifying Ehrlichia species
US20240230670A1 (en) Markers for renal disease
AU2017204520B2 (en) Markers for renal disease
WO2007038579A1 (fr) L'expression du bas permettant de prevoir la reponse au traitement d'une maladie hematologique

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200109

EEER Examination request

Effective date: 20200109

EEER Examination request

Effective date: 20200109

EEER Examination request

Effective date: 20200109

EEER Examination request

Effective date: 20200109

EEER Examination request

Effective date: 20200109